Analysis of the Prognostic Potential of Schlafen 11, Programmed Death Ligand 1, and Redox Status in Colorectal Cancer Patients.
PD-L1
SLFN11
biomarkers
colorectal cancer
oxidative stress
redox status
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
08
08
2023
revised:
13
09
2023
accepted:
20
09
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The Schlafen 11 (SLFN11) protein has recently emerged as pivotal in DNA damage conditions, with predictive potential for tumor response to cytotoxic chemotherapies. Recent discoveries also showed that the programmed death ligand 1 (PD-L1) protein can be found on malignant cells, providing an immune evasion mechanism exploited by different tumors. Additionally, excessive generation of free radicals, redox imbalance, and consequential DNA damage can affect intestinal cell homeostasis and lead to neoplastic transformation. Therefore, our study aimed to investigate the significance of SLFN11 and PD-L1 proteins and redox status parameters as prognostic biomarkers in CRC patients. This study included a total of 155 CRC patients. SLFN11 and PD-L1 serum levels were measured with ELISA and evaluated based on redox status parameters, sociodemographic and clinical characteristics, and survival. The following redox status parameters were investigated: spectrophotometrically measured superoxide dismutase (SOD), sulfhydryl (SH) groups, advanced oxidation protein products (AOPP), malondialdehyde (MDA), pro-oxidant-antioxidant balance (PAB), and superoxide anion (O
Identifiants
pubmed: 37894765
pii: ijms242015083
doi: 10.3390/ijms242015083
pmc: PMC10606719
pii:
doi:
Substances chimiques
CD274 protein, human
0
B7-H1 Antigen
0
Antioxidants
0
SLFN11 protein, human
0
Nuclear Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Education, Science and Technological Development of the Republic of Serbia
ID : 451-03-47/2023-01/ 200110
Références
Int J Clin Oncol. 2015 Dec;20(6):1140-6
pubmed: 25947545
J Trauma. 1991 Jan;31(1):32-5
pubmed: 1846013
Biomolecules. 2019 Nov 13;9(11):
pubmed: 31766246
Mol Ther. 2021 Feb 3;29(2):587-596
pubmed: 33333293
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
Histol Histopathol. 1997 Apr;12(2):525-35
pubmed: 9151141
Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
Cancer Sci. 2022 Feb;113(2):784-795
pubmed: 34808009
Br J Cancer. 2021 Nov;125(10):1333-1340
pubmed: 34294893
Int J Cancer. 2009 May 15;124(10):2406-15
pubmed: 19142968
Mutat Res. 2009 Mar 31;674(1-2):36-44
pubmed: 18977455
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Anticancer Drugs. 2014 Nov;25(10):1175-81
pubmed: 25089570
Br J Cancer. 2021 Jul;125(1):65-77
pubmed: 33785877
Cell Rep. 2020 Mar 24;30(12):4137-4151.e6
pubmed: 32209474
Nat Commun. 2022 Sep 17;13(1):5464
pubmed: 36115853
BMC Cancer. 2015 Nov 02;15:833
pubmed: 26525741
Clin Biochem. 2007 Feb;40(3-4):248-54
pubmed: 17196578
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Biol Chem. 1972 May 25;247(10):3170-5
pubmed: 4623845
Int J Mol Sci. 2016 Jan 14;17(1):
pubmed: 26784176
J Biol Chem. 2004 Aug 13;279(33):34643-54
pubmed: 15155719
Cancers (Basel). 2021 Feb 27;13(5):
pubmed: 33673398
BMC Cancer. 2014 May 16;14:336
pubmed: 24886281
Atherosclerosis. 2015 Jul;241(1):192-8
pubmed: 26016451
Biomarkers. 2009 Nov;14(7):465-72
pubmed: 19863184
BMC Cancer. 2020 Nov 20;20(1):1123
pubmed: 33218331
Curr Opin Drug Discov Devel. 2009 Mar;12(2):240-5
pubmed: 19333869
Biomarkers. 2006 Nov-Dec;11(6):562-73
pubmed: 17056475
J Clin Med. 2022 Aug 17;11(16):
pubmed: 36013050
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
Naunyn Schmiedebergs Arch Pharmacol. 2017 Jun;390(6):557-565
pubmed: 28229171
Br J Cancer. 2021 Mar;124(5):857-859
pubmed: 33328609
Ther Adv Chronic Dis. 2020 Jun 27;11:2040622320936417
pubmed: 32647560
J Clin Pathol. 2018 Mar;71(3):189-194
pubmed: 29097600
J Natl Cancer Inst. 2012 Oct 17;104(20):1548-61
pubmed: 22914790
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5
pubmed: 22927417
Cancers (Basel). 2020 Nov 11;12(11):
pubmed: 33187272
Health Expect. 2019 Oct;22(5):1050-1057
pubmed: 31273909
Cancer Immunol Immunother. 2020 Dec;69(12):2533-2546
pubmed: 32577816
Oncotarget. 2017 Apr 25;8(17):28575-28587
pubmed: 28212573
Cancer Res. 2008 Mar 15;68(6):1777-85
pubmed: 18339858
Kidney Int. 1996 May;49(5):1304-13
pubmed: 8731095
Biomed Res Int. 2013;2013:725710
pubmed: 23762854
Tumour Biol. 2016 Jun;37(6):8413-23
pubmed: 26733168
Mol Cell. 2018 Feb 1;69(3):371-384.e6
pubmed: 29395061
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Front Immunol. 2022 Aug 25;13:922138
pubmed: 36090985
PLoS One. 2015 Mar 03;10(3):e0118612
pubmed: 25734426
PLoS One. 2019 Nov 4;14(11):e0224267
pubmed: 31682620
Curr Oncol. 2021 Dec 13;28(6):5356-5383
pubmed: 34940086
J Biol Chem. 2017 May 12;292(19):7866-7887
pubmed: 28330872
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Oncotarget. 2016 Jan 19;7(3):3084-97
pubmed: 26625211
Radiol Oncol. 2021 Jan 12;55(1):7-17
pubmed: 33885236
Theranostics. 2020 Mar 25;10(10):4627-4643
pubmed: 32292519